Drugs / ginsenoside RE
ginsenoside RE
Trials 0
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT00781534 Comparator | Sep 2003 → Dec 2004 | diabetes mellitus | Washington University School of Medicine | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ginsenoside RE | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00781534 ↗ |
| Known as | Chikusetsusaponin ivc | ChEMBL registry synonym — accepted as the source's own label CHEMBL510095 ↗ |
| Known as | Ginsenoside b2 | ChEMBL registry synonym — accepted as the source's own label CHEMBL510095 ↗ |
| Known as | NSC-308877 | ChEMBL registry synonym — accepted as the source's own label CHEMBL510095 ↗ |
| Known as | Panaxoside re | ChEMBL registry synonym — accepted as the source's own label CHEMBL510095 ↗ |
| Known as | Sanchinoside re | ChEMBL registry synonym — accepted as the source's own label CHEMBL510095 ↗ |
| Route | Oral | “CONCLUSIONS: Oral ginseng or ginsenoside Re therapy does not improve β-cell function or IS in overweight/obese subjects with impaired glucose tolerance or newly diagnosed diabetes.” PMID 21411505 ↗ Mar 2011 |